Milestones

January -

At the meeting of the Board of Directors of the Company held on 31.01.2012,
Mr. R. S. Hugar stepped down as the Chairman of the Board of Directors due to his other pre-occupations and commitments. However, he will continue as the Independent Director on the Board of the Company.
In his place, the Board appointed the incumbent Managing Director, Mr. Premchand Godha, as the Chairman of the Board of Directors and re-designated him as the Chairman & Managing Director of the Company.

Ipca’s formulation plant at Dehradun, received IDMA Quality Excellence Awards 2011.
Category: Formulations Units - Companies with Total Annual turnover Above Rs.100 crores. This Silver Award was presented on the 50th Annual Day Celebrations of IDMA on 6^th January 2012 in Mumbai.

April -

Ipca’s Fixed dose combination Artesunate + Amodiaquine tablets (Strengths – 25mg + 67.5mg, 50mg + 135mg and 100mg + 270mg) is approved under the WHO Prequalification Programme.
This is the first generic product of fixed-dose Artesunate + Amodiaquine tablets prequalified by WHO.

At the meeting of the Board of the Directors of the company held on 13^th April, 2012, Mr. Dev Parkash Yadava was appointed as an Additional Director of the Company.

June -

Ipca’s domestic marketing (Altus division) launched Olficef, a combination oral antibiotic containing Ofloxacin and Cefixime.

October -

Pharmaceuticals Export Promotion Council of India honoured Ipca Laboratories Limited for its outstanding contribution to India’s Pharmaceutical Exports for the year 2011 – 12 at INDIA – ASIA – PACIFIC Pharma Business Meet at Hyderabad.
Joint Managing Director, Mr. Ajit Kumar Jain received the ‘Pharmexcil Outstanding Exports Award 2011 – 12’ on the behalf of Ipca from Hon’ble Chief Minister of Andhra Pradesh, Shri N. Kiran Kumar Reddy and Minister for Major Industries, Sugar, Commerce and Export Promotion, Smt. Geeta Reddy J. in the presence of several Government dignitaries and senior officials from the Department of Commerce.

November -

Dun & Bradstreet, the world’s leading provider of global business information, knowledge and insight, in association with Export Credit Guarantee Corporation of India Ltd (ECGC) announced the ‘ECGC – D&B Indian Exporters’ Excellence Awards 2012’ to recognize the contribution of the Exporters to the Indian economy.

1. Exporter with the Best Risk Management Practices - Ipca Laboratories
Limited, Second Runner-up

2. Most Diversified Exporter - Ipca Laboratories Limited, Winner
January -

Launched, Laxtaz the new age laxative that combines Ispaghula with Lactitol.
The combination effectively relieves constipation by restoring colonic Mass, Motion and Microflora. Hence Laxtaz is positioned as the '3 M Laxative'.

Launched CTD (Chlorthalidone), a novel antihypertensive which has the longest half life and is more effective than Amlodipine and Lisinopril.

February -

SEZ Pithampur (Indore) formulations manufacturing unit has been certified for Good Manufacturing Practices (GMP) by UK-MHRA (Medicines and Healthcare Products Regulatory Agency, U.K). This is the first regulatory approval for Pithampur unit.
And this is the fourth manufacturing unit of the Company to have received such approval from UK-MHRA.

Ipca's formulation manufacturing unit at Pithampur (SEZ) was approved by WHO (World Health Organization)-Geneva.

March -

Launched new division Ipca-Dynamix, which will cater to cardiovascular, gastrointestinal, antibacterial, respiratory segments.

Clinical study entitled "Efficacy and Safety of Aceclofenac-CR and Aceclofenac in the treatment of knee osteoarthritis: A six week, comparative, randomized, multicentric, double-blind study has been published in The Journal of Pain - Official Journal of the American Pain Society (5-year impact factor 4.2).

Clinical study entitled "Evaluation of Efficacy and Tolerability of Glimepiride and Metformin Combination: A Multicentric Study in Patients with Type-2 Diabetes Mellitus, Uncontrolled on Monotherapy with Sulfonylurea or Metformin" is published in American Journal of Therapeutics.

Pre-clinical study entitled "Evaluation of anti-Inflammatory activity of Hydroxychloroquine and Simvastatin combination in experimental animals" is published in Research Journal of Pharmaceutical, Biological and Chemical Sciences (RJPBCS).

Launched new division, IPM, carved out from Activa division, which will manage pain segments

April -

Pre-clinical study entitled "Evaluation of anti-inflammatory activity of Etodolac and Colchicine combination in experimental animals" is published in International Journal of Pharmacology and Therapeutics.

Clinical study entitled "Zaltoprofen, a non-inferior alternative to diclofenac for the treatment of primary knee osteoarthritis -- a comparative evaluation of efficacy and safety in a 4-week, multicentric, randomized, double-blind, double-dummy trial" is published in Expert Opinion on Pharmacotherapy (Impact Factor 2.1).

July -

Launched Rapiclav^®1g in West African countries of Ivory Coast, Mali, Senegal, Burkina Faso, Benin & Nigeria.

August -

Mr. Prashant Godha appointed as Executive Director

Ipca Laboratories Ltd. acquires 100% share capital of Onyx Research Chemicals Ltd. holding Company of Onyx Scientific Ltd. through its wholly owned subsidiary Ipca Laboratories U.K. Ltd. The acquisition brings together two Contract Manufacturing Organisations (CMOs) to better serve their customers on a global basis.

Onyx Scientific has been a chemistry solutions provider for over a decade and will continue to operate out of the Silverbriar (Sunderland, UK) facility under the Onyx Scientific trade name. Onyx's capabilities in chemistry services for Medicinal, Preclinical and Phase-I/II programs will dovetail effectively with Ipca's capabilities in supporting Phase II to Commercial scale programmes.

September -

Lumerax, the segment leader in Artemether-Lumefantrine combination, has entered the prestigious league of top 300 brands of Indian Pharma market as per ORG-IMS Data. Lumerax has a proud history of being the first brand of 'Artemisinin based Combination Therapy (ACT)' launched in accordance with the erstwhile WHO guidelines.

An Advance Hypertension Summit – Chlorthalidone in Renaissance was organized. The highlight of this summit was the speaker's credentials. The eminent speaker for the symposia was Dr. Aram Chobanian, who is the Chairperson for JNC VII committee. Dr Chobanian was also on the panel of almost all JNCs and was the Chairperson for ALLHAT committee.

Clinical study entitled "Comparative evaluation of efficacy and safety of etodolac and diclofenac sodium injection in patients with postoperative orthopedic pain" conducted by Clinical Research and Development Department is published in Vol. 27, Issue 11 of an international peer reviewed journal Current Medical Research & Opinion (CMRO, Impact Factor 2.7).

This is the first study in the world to provide comparative clinical evidence of efficacy and safety of etodolac injection with respect to diclofenac injection in patients with post operative pain.

October -

New Corporate Logo launched in CPhI, Frankfurt which also synchronize well with the auspicious Indian festival, Diwali.

December -

Zerodol – P has been awarded "Special Life Time Award" by IPHMR & CMARC (Institute of Pharmaceutical & Healthcare Management And Research in association with C MARC).
The current areas of interest chosen were:
a) Successful Premium Brands,
b) Best New Launch Brand &
c) Best Brand Extension
January -

Clinical study entitled "Efficacy and Tolerability of a Fixed-Dose Combination of Metoprolol Extended Release/Amlodipine in Patients with mild-to-moderate Hypertension" published in Clinical Drug Investigation; an Adis publication.

The "Clinical Drug Investigation" is an international peer-reviewed journal publishing original findings of the world's leading drug research.

February -

New CRAMS division - Covenance, launched, which caters to the outsourcing needs of the pharma companies.

March -

New domestic Division, 'Ipca Nephrosciences' launched, which caters to Nephrologists and deals with kidney transplant and dialysis patients.

Ipca launches another domestic cardio-diabetic marketing division '3D'.

June -

Ipca Laboratories Ltd. - Among the 100 Best Companies to work in India. The survey was conducted throughout India jointly by The Great Place to Work^® Institute, India and The Economic Times across various organizations as a part of the 'India's Best Companies to Work For- 2010'. Study results were published in The Economic Times dated 20th June, 2010.

Clinical study entitled "Efficacy and safety of Aceclofenac and Drotaverine fixed-dose combination in the treatment of primary dysmenorrhoea: a double-blind, double-dummy, randomized, comparative study with Aceclofenac" is published in European Journal of Obstetrics & Gynaecology and Reproductive Biology. It is the leading clinical journal which provides a forum for scientific and clinical professional communication in obstetrics and gynaecology throughout the world.

Clinical study entitled "Evaluation of Efficincy and Tolarability of Gliclazide and Metformin Combination : A Multicentric Study in Patients with Type-2 Diabetes Mellitus, Uncontrolled on Monotherapy with Sulfonylurea or Metformin" is published in American Journal of Therapeutics.

July -

Mr. A. K. Jain, re-designated as Joint Managing Director.

Ipca - Aurangabad API manufacturing plant assessed by AFAQ-EAQA as complies with the Occupational Health & Safety Management System requirements of OHSAS 18001:2007.

AFNOR (Certification) certifies that the management system implemented by Ipca - Aurangabad, API manufacturing plant for manufacturing and supply of Bulk Drugs (Active Pharmaceutical Ingredients) has been assessed and found to meet the requirements of ISO 14001:2004.

Seventh Clinical Trial in Pain Management published in "The Clinical Journal of Pain - official journal of eastern pain association" The Clinical Journal of Pain is a peer-reviewed journal that explores all aspects of pain and its effective treatment, bringing readers the insights of leading anaesthesiologists, surgeons, internists, neurologists, orthopaedists, psychiatrists and psychologists, clinical pharmacologists and rehabilitation medicine specialists.

August -

United States Patent office has issued patent rights to Ipca for its novel process for manufacturing of API Isotretinoin.

This is the Nineth patent granted by United States Patent office on API to Ipca.

September -

Ipca Laboratories Ltd. received Pharmexcil Gold Patent award for the year 2009-2010, for the second consecutive year. This award was in recognition of commendable contribution in the field of API. The award was given for overall group of granted patents in API category during the year 2009-10.

Mint newspaper published 500 Best Performing midsize firms compiled by Inc. magazine and Ipca ranks at 51^st position.

October -

Ipca joins hands with BMC (Brihanmumbai Municipal Corporation) to fight against Malaria. BMC decided to release a film on 'Malaria & its Prevention'. Ipca was called to partner with them due to our long standing credibility and expertise in this field.

November -

'Ipca Contact', in-house quarterly magazine wins 'Bronze' medal in Headline Category in ABCI 50^th Awards Nite.

December -

Ipca - Ratlam formulations plant ranked third position in the National Energy Conservation Award 2010.

Ipca - Dehradun formulation plant at Dehradun receives 'Uttarakhand Energy Conservation Award 2010'. Ipca - Dehradun plant stood first in entire State of Uttarakhand.
January -

Study entitled "Comparative Evaluation of Efficacy and Safety of Cefotaxime-Sulbactam with Amoxicillin-Clavulanic Acid in Children with lower respiratory tract infections" conducted by Clinical Research Department accepted for poster symposium by 2^nd Congress of the European Academy of Pediatrics, held at Nice, France.

The first preclinical study conducted by Clinical Research Department entitled "In Vivo Antimalarial Activity of Oral Beta-Arteether and Piperaquine Combination" published in Italian Journal "Pharmacology Online".

Clinical trial conducted by Clinical Research Department of Ipca entitled "Comparative Evaluation of Efficacy and Safety of Cefotaxime-Sulbactam with Amoxicillin-Clavulanic Acid in Children with lower respiratory tract infections" published in "Expert Opinion on Pharmacotherapy".

Ipca's Green Technology Department, published first research paper on "Optimization of extract conditions and HPTLC-UV method of determination of quinine in different extracts of Cinchona spp. bark" in an international peer-reviewed Journal "Records of Natural Products". Green Technology Department is working on production of phytopharmaceuticals like, Artemisinin and Quinine sulphate. This department is also involved in contract farming of Artemisia annua.

European patent office has issued patent rights to Ipca for its method of making Carvedilol with patent number EP1741700.

United States patent office has issued patent rights to Ipca for its method of making Tramadol with patent number US7470816.

March -

European Patent office has issued patent rights to Ipca for its method of making Alendronic acid with patent number EP1803727.

April -

Clinical trial entitled "A randomized, multicentric, comparative evaluation of aceclofenac-paracetamol combination with aceclofenac alone in Indian patients with osteoarthritis flare-up" has been published in "Expert Opinion on Pharmacotherapy" journal in UK.

July -

A randomized, comparative, multicentric evaluation of atenolol/amlodipine combination with atenolol alone in essential hypertensive patients was published in "American Journal of Therapeutics" Philadelphia.

Aceclofenac-tizanidine in the treatment of acute low back pain: a doubleblind, double-dummy, randomized, multicentric, comparative study against aceclofenac alone was published in "European Spine Journal", Switzerland.

A randomized, comparative study evaluating the efficacy and tolerability of losartan-low dose chlorthalidone (6.25 mg) combination with Losartan hydrochlorothiazide (12.5 mg) combination in Indian patients with mild-to-moderate essential hypertension was published in "Expert Opinion on Pharmacotherapy" UK.

United States patent office has issued patent rights to Ipca for its method of making Ondansetron with patent number US7547791.

September -

WHO/MMV organized 4^th Antimalarial conference first time in India with Ipca as the primary partner.

October -

Ipca Laboratories Ltd. received Pharmexcil "Gold Patent award" for the year 2008-2009. Ipca Laboratories Ltd. bagged this award in recognition of commendable contribution in the field of API. Pharmexcil is setup by Ministry of Commerce and Industry, Govt. of India.

Clinical study entitled "Antihypertensive Efficacy of Metoprolol XL/Low Dose Chlorthalidone Combination: A Randomized, Comparative study in Indian patients with mild-to-moderate Essential Hypertension" published in European Journal of Medical Research.

November -

Ipca - Ratlam celebrates Silver Jubilee of its existence.

December -

United States patent office has issued patent rights to Ipca for its method of making Methylphenidate with patent number US7459467.

IDMA's Quality Excellence Award 2009 - Silver Medal honored to Ipca - Dehradun plant.

Ipca - Dehradun formulations plant, received award for 'Energy Conservation' from Uttrakhand Renewable Energy Development Agency (UREDA) on the occasion of National Energy Conservation Day.
January -

'Ipca Who' Brochure wins ABCI Gold Award, (Association of Business Communicators of India) 48th annual Awards for Excellence in Creative Business Communications.

Altus division launches Gardcef, a novel combination of Ceftazidime + Sulbactam.

February -

Tonira Pharma's Nandesari unit (API plant at Baroda) receive US-FDA approval.

March -

Ipca - Piparia, Formulations manufacturing unit receive MHRA-UK approval. This is the 3rd plant after Athal and Kandla receiving this approval.

April -

WHO prequalify Ipca dossier of Artesunate + Amodiaquine co-blister making Ipca the 2nd company in the world and the 1st Indian company to receive this prequalification.

Ipca - Piparia, Formulations manufacturing unit receive US-FDA approval.

Ipca - Ratlam, API manufacturing unit receive US-FDA re-approval.

May -

WHO Geneva re-approved Ipca - Ratlam, API manufacturing unit for the third time.

Ipca Laboratories Ltd. has been awarded third position in, case-study presentation during the "10^th National Suggestion Summit" organized by INSSAN-Northern Indian Chapter (NIC), New Delhi.

Ipca - Ratlam, API manufacturing unit got approval from Pharmaceutical and Medical Devices Agency (PMDA), Japan

Ipca completes management acquisition of Tonira Pharma Ltd. through public offer.

Ipca - Ratlam, Formulations manufacturing unit receive approval from Colombia Invima.

June -

Ipca became the first company to launch formulation brand HCQS (Hydroxy Chloroquine Sulphate) in Kenya after innovator brand.

Ipca Laboratories Ltd., bags D&B - ECGC Indian Exporters Excellence Award - Topmost Exporter of Pharmaceutical Large Sector.

Ipca receives approval from US FDA to manufacture Propranolol Hydrochloride Tablets.

July -

Clinton Foundation announces New Agreements on Supply of anti-malarial Drugs, inter-alia, with Ipca.

August -

Dr. Paul Bacon, Professor Emeritus, University of Birmingham, UK, a world renowned authority in Rheumatoid arthritis addressed leading clinicians in six metro towns in India.

November -

'Ipca Contact' wins Silver medal in ABCI's (Association of Business Communicators of India) 48th annual Awards for Excellence in Creative Business Communications.

December -

Ipca Laboratories Ltd. - Hycare division wins 'The Best Participation Award' at the conference of CSI (Cardiological Society of India) 2008.

Tonira Pharma's API manufacturing plants situated at Ankleshwar and Nandesari receive PMDA-Japan approval.
January -

Ipca - Ranbaxy Alliance receive U.S. FDA marketing approval for Atenolol Tablets.

March -

Ipca launched eighth domestic marketing division - Altus which caters to intensivists and surgeons.

New Biotech Research & Development Unit was inaugurated at Mumbai.

June -

Ipca - Ranbaxy Alliance receive U.S. FDA marketing approval for Hydroxychloroquine Sulfate (HCQS) Tablets.

July -

Ipca - Ranbaxy Alliance receive U.S. FDA marketing approval for Hydrochlorothiazide (HCTZ) Tablets.

August -

Ipca - Ranbaxy Alliance receive U.S. FDA marketing approval for Metformin HCl Tablets.

September -

Acquisition of 100% shareholding of Formulation Dossier registration holding companies in Australia and New Zealand. The Australian company is currently holding five formulation registration dossiers in that country.

October -

Ipca Laboratories Ltd. has been awarded by Forbes Inc., as one of the 'Best under a Billion' Forbes Global's 200 Best Small Companies, 2007. In the past, company has received same award for three consecutive years' 2003, 2004 and 2005.

December -

Ipca - Ratlam received 2^nd prize in the 'National Energy Conservation Award-2007' in Drug and Pharmaceuticals sector from the Bureau of Energy efficiency under the Ministry of Power, Government of India, New Delhi.
Ipca launches Fixed dose ACT combination for treatment of malaria and stops manufacturing of single ingredient Oral Artemisinin derivatives.

Ipca enters into strategic alliance with Ranbaxy Pharmaceuticals Inc. for the U.S market.

Ipca new formulations plant at Dehradun commenced operation on 5^th May.
Merger of Innotech Pharma Limited with Ipca in August, 2005.

Ipca acquires cardiac brand Isordil from Wyeth Limited.

Forbes Asia, a leading US business magazine selected Ipca, for the third consecutive year, as one among the first 200 'Best under a Billion Company' in Asia.
Commissioned new Formulations manufacturing plant at Silvassa.

Ipca Laboratories Ltd. received 'Lifetime Achievement Award' for the year 2002-03 from CHEMEXIL (Basic Chemicals, Pharmaceuticals & Cosmetics Export Promotion Council) for export promotion over the years.

CDRI licenses novel Antimalarial compound to Ipca.

Ipca - Ratlam, API manufacturing facility inspected by US-FDA and the facility was found to be in compliance with global GMP requirements. The plant and the facilities have been recommended for manufacturing Atenolol, Propranolol Hydrochloride, Hydroxychloroquine Sulphate and Chloroquine Phosphate.

Forbes Asia, a leading US business magazine selected Ipca, for the second consecutive year as one among the first 200 'Best under a Billion Company' in Asia.
Launched new domestic marketing division - Activa, dedicated to Rheumatology Care. First Company in India to have such division for marketing super-speciality molecules.

Launched new domestic marketing division - Hycare, dedicated to Cardio-Diabetology segments.

Wholly owned subsidiary 'Ipca Pharmaceuticals Inc.' incorporated in United States of America.

Wholly owned subsidiary 'Ipca (UK) Ltd.' incorporated in United Kingdom.

Forbes, a leading US business magazine, selected Ipca among its top 200 successful, rising companies outside USA, with sales under USD 1 Billion.
Launched new domestic marketing division - Intima, to promote established brands with a focus on micro-interior marketing.

Wholly owned subsidiary 'Laboratories Ipca Do Brasil Ltd.' incorporated in Brazil.
'Trishul' the highest award was conferred on Ipca Laboratories Ltd. by CHEMEXIL (Basic Chemicals, Pharmaceuticals & Cosmetics Export Promotion Council) for outstanding export performance.

Launched new domestic marketing division - Innova, to promote speciality products in therapeutic segments of Psychiatry, Neurology and Dermatology.

Ipca acquired 'National Druggists (Pty) Ltd.' in South Africa.

'Ipca Pharma Nigeria Ltd.' incorporated in Nigeria.
Received ISO 9001 certification for Ipca Athal formulations Plant.
First to introduce formulation of Hydroxychloroquine Sulphate under brand name 'HCQS' in India.
Launched 3C (Comprehensive Cardiac Care) Domestic Marketing Division, dedicated to promote cardiac care products.

Ipca - Athal, Formulations manufacturing unit received prestigious approval from UK-Medicines and Healthcare products Regulatory Agency (MHRA) formerly known as UK- Medicines Control Agency (MCA).

Ipca - Athal, Ipca - Kandla and Ipca - Ratlam Formulations manufacturing plants received the prestigious approval from MCC (Medicines Control Council) South Africa.
Ipca commissioned new API R&D Centre at Mumbai.
Ipca commissioned modern formulations plant at Athal (Silvassa).
Maiden Public Issue of shares.

Ipca acquired API manufacturing plant from BDH Pharmaceuticals (a subsidiary of E-Merck) at Indore.
Acquired Hoechst India's formulations unit at Kandla.
Ipca first API Plant for manufacturing of Chloroquine Phosphate, set up at Ratlam.

Production of API Atenolol, for the first time in India, commenced at Ratlam.
Production of Pyrantel Pamoate API commenced for the first time in India.

Ipca commenced manufacturing of Injectables at the Ratlam formulations unit.
First API plant commissioned at Ratlam.

Ipca second Formulations manufacturing plant commissioned at Ratlam.
First company after Eli Lilly to develop a pre-constituted formulation of Erythromycin Estolate (Eltocin^® Liquid).
R&D-API and R&D-Formulation development departments set up to provide technology based products.
Ipca launched formulations of Bromhexine for the first time in India.
Ipca launched formulations of Metoclopramide under brand name 'Perinorm'^® for the first time in India.

Launched 'Ipca Contact', Company's in-house Magazine
Ipca started marketing of sugarcoated Chloroquine tablets, first time in India.

About Us

Latest @ Ipca